Please assess the completion status of the following clinical trial:

Trial Title: Prediction of Tumor Shrinkage in Acromegaly

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* No previous treatment for acromegaly~Exclusion Criteria:~* primary surgery~* concomitant hyperprolactinemia requiring combined somatostatin analogues and dopamine-agonist treatment~* primary treatment with lanreotide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: None): Newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment with LAR

Based on this trial design, predict the completion outcome and termination type (if applicable).